Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4.
Montesel A, Pakeer Muhammed R, Chandak S, Kazantzis D, Thottarath S, Chandra S, Chong V, Burton BJL, Menon G, Pearce I, McKibbin M, Kotagiri A, Talks J, Grabowska A, Ghanchi F, Gale R, Giani A, Yamaguchi TCN, Sivaprasad S. Montesel A, et al. Among authors: kotagiri a. Eye (Lond). 2024 Apr 23. doi: 10.1038/s41433-024-03087-0. Online ahead of print. Eye (Lond). 2024. PMID: 38653751
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC; VICI trial investigators. Lotery A, et al. Lancet. 2020 Jan 25;395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2. Lancet. 2020. PMID: 31982075 Clinical Trial.
Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes.
Sivaprasad S, Ghanchi F, Kelly SP, Kotagiri A, Talks J, Scanlon P, McGoey H, Nolan A, Saddiq M, Napier J; DRAKO study group. Sivaprasad S, et al. Among authors: kotagiri a. Eye (Lond). 2022 Jan;36(1):64-71. doi: 10.1038/s41433-021-01624-9. Epub 2021 Jul 9. Eye (Lond). 2022. PMID: 34244670 Free PMC article.
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel.
Bailey C, Cackett P, Kotagiri A, Mahmood S, Minos E, Narendran N, Patwardhan A, Sim DA, Morgan-Warren P, O'Neil C, Straw K. Bailey C, et al. Among authors: kotagiri a. Eye (Lond). 2023 Jun;37(9):1916-1921. doi: 10.1038/s41433-022-02264-3. Epub 2022 Oct 7. Eye (Lond). 2023. PMID: 36207506 Free PMC article.
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes.
Sivaprasad S, Ghanchi F, Kelly SP, Kotagiri A, Talks J, Scanlon P, McGoey H, Nolan A, Saddiq M, Napier J, Morgan-Warren P. Sivaprasad S, et al. Among authors: kotagiri a. Eye (Lond). 2023 Aug;37(12):2527-2534. doi: 10.1038/s41433-022-02367-x. Epub 2023 Jan 18. Eye (Lond). 2023. PMID: 36653595 Free PMC article.
A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1.
Chorev M, Haderlein J, Chandra S, Menon G, Burton BJL, Pearce I, McKibbin M, Thottarath S, Karatsai E, Chandak S, Kotagiri A, Talks J, Grabowska A, Ghanchi F, Gale R, Hamilton R, Antony B, Garnavi R, Mareels I, Giani A, Chong V, Sivaprasad S. Chorev M, et al. Among authors: kotagiri a. J Clin Med. 2023 Apr 20;12(8):3013. doi: 10.3390/jcm12083013. J Clin Med. 2023. PMID: 37109349 Free PMC article.
36 results